Condition
High Bleeding Risk Patients
Total Trials
4
Recruiting
0
Active
1
Completed
1
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
0%
0 trials in Phase 3/4
Results Transparency
0%
0 of 1 completed with results
Key Signals
100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (3)
Trial Status
Unknown1
Not Yet Recruiting1
Completed1
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 1 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT07238764Not ApplicableCompletedPrimary
OCT-based DAPT Cessation in HBR Patients
NCT07140133Not Yet RecruitingPrimary
Dual Anti-Platelet Optimized Stent for High Bleeding Risk Patient
NCT05643430Not ApplicableActive Not Recruiting
ULTRA LONG: BioFreedom Ultra
NCT01930903Not ApplicableUnknown
PaneLux PTCA : Proposing an Alternative Treatment to patiEnts for Whom DES Implantation is Not Indicated, Thanks to Pantera LUX Drug Eluting Balloon
Showing all 4 trials